Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma - Trial NCT06285019
Access comprehensive clinical trial information for NCT06285019 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 65 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fudan University
Timeline & Enrollment
Phase 2
Dec 01, 2023
Dec 31, 2025
Primary Outcome
objective response rate (ORR)
Summary
This is a single-center, single-arm, phase II clinical study, to explore the efficacy and
 safety of modified TOMOX-HAIC combined with sintilimab and bevacizumab biosimilar as first
 line treatment in patients with advanced hepatocellular carcinoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06285019
Non-Device Trial